 |
 |
Clinical Trial Name - Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.
| Original Study ID : KUH5070206 |
| Secondary ID : EudraCT 2008-000597-21 |
| NCT ID : NCT00757198 |
| Brief Title : Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery. |
| Official Title : Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery. |
| Brief Summary : Prospective double blind study comparing two remifentanil dosing protocols (0.1 and 0.3 mcg/kg/min) during cardiac surgery. Main outcome measures are postoperative opioid requirements (PCA oxycodone) and postoperative pain (VAS, verbal rating scale). |
| Source : Kuopio University Hospital |
| Overall Status : Recruiting |
| Start Date : September 2008 |
| End Date : March 2011 |
| Completion Date : March 2011 |
| Official Title : Phase 4 |
| Phase : Interventional |
| Study Design : Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study |
| Enrollment : 90 |
| Verification Date : April 2009 |
| First Received Date : September 22, 2008 |
| Trial Eligibility |
| Criteria : Inclusion Criteria: - Coronary artery bypass grafting patients Exclusion Criteria: - Psychiatric disorders, sleep apnea, cardiac insufficiency |
| Gender : Both |
| Minimum Age : 18 Years |
| Maximum Age : 80 Years |
| Healthy Volunteers : No |
| Facilities |
| Facility Name : Kuopio University hospital |
| Status : Recruiting |
| City : Kuopio |
| Zip Code : 70210 |
| Country : Finland |
| OutComes |
| Primary OutComes |
| Measure : Postoperative opioid (oxycodone) consumption |
| Time Frame : Postoperatively 48 hours |
| Safety issue : No |
| Interventions |
| Type : Drug |
| Name : remifentanil |
| Description : remifentanil infusion |
| Type : Drug |
| Name : remifentanil |
| Description : remifentanil infusion |
Search For Specialist
Types of Treatments
| Search Trials By |
| Research |
| Most Popular Trials |
| Library |
| Discuss |